trending Market Intelligence /marketintelligence/en/news-insights/trending/36iilPWRt5MWpUQmfa9Pkg2 content esgSubNav
In This List

US FDA clears Loxo Oncology's application for cancer drug

Blog

Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch


US FDA clears Loxo Oncology's application for cancer drug

The U.S. FDA cleared Loxo Oncology Inc.'s investigational new drug application for its next-generation tyrosine receptor kinase, or TRK, inhibitor, LOXO-195, to treat patients with TRK fusion cancers who become resistant while receiving another TRK inhibitor, such as larotrectinib.

Loxo plans to develop the product as a sequential treatment, to follow larotrectinib or another TRK inhibitor, to extend the total time of benefit from TRK inhibition.

The drug will initially be studied in a phase 1/2 trial, whose primary objective will be to determine the maximum tolerated dose or recommended dose for further study.